DTIL PRECISION BIOSCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2026, PRECISION BIOSCIENCES INC reported revenue of $0 (down 100.0% from a year earlier), net income of −$32.7M and diluted EPS of −$1.26; over the last four quarters revenue was $45.1M and net income −$52.7M; for the fiscal year ended December 2025 revenue was $34.3M, down 50.1% on the year before.
DTIL annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $34.3M, gross profit n/a, operating income −$52.1M, net income −$45.7M (margin -133.4%), EPS −$3.56
- Fiscal year ended Dec 2024: revenue $68.7M, gross profit n/a, operating income −$26.2M, net income $7.17M (margin 10.4%), EPS $1.04
- Fiscal year ended Dec 2023: revenue $48.7M, gross profit n/a, operating income −$43.7M, net income −$61.3M (margin -125.8%), EPS −$15.96
- Fiscal year ended Dec 2022: revenue $25.1M, gross profit n/a, operating income −$62.3M, net income −$112M (margin -444.8%), EPS −$38.10
- Fiscal year ended Dec 2021: revenue $116M, gross profit n/a, operating income −$39.4M, net income −$30.6M (margin -26.5%), EPS −$0.52
DTIL quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0 (down 100.0% year over year), net income −$32.7M, EPS −$1.26
- Quarter ended Mar 31, 2026: revenue $10.8M (up 37272.4% year over year), net income −$18.4M, EPS −$0.75
- Quarter ended Dec 31, 2025 (from the annual report): revenue $34.2M (up 5261.1% year over year), net income $20.1M, EPS $2.62
- Quarter ended Sep 30, 2025: revenue $13.0K (down 97.7% year over year), net income −$21.8M, EPS −$1.84
- Quarter ended Jun 30, 2025: revenue $18.0K (down 100.0% year over year), net income −$23.5M, EPS −$2.13
- Quarter ended Mar 31, 2025: revenue $29.0K (down 99.8% year over year), net income −$20.6M, EPS −$2.21
- Quarter ended Dec 31, 2024 (from the annual report): revenue $638K (down 90.9% year over year), net income −$17.7M, EPS −$3.08
- Quarter ended Sep 30, 2024: revenue $576K (down 95.6% year over year), net income −$16.4M, EPS −$2.25
- Quarter ended Jun 30, 2024: revenue $49.9M (up 152.2% year over year), net income $32.7M, EPS $4.67
- Quarter ended Mar 31, 2024: revenue $17.6M (up 100.3% year over year), net income $8.59M, EPS $1.70
- Quarter ended Dec 31, 2023 (from the annual report): revenue $7.04M (down 33.6% year over year), net income −$16.3M, EPS −$3.98
- Quarter ended Sep 30, 2023: revenue $13.1M (up 78.2% year over year), net income −$8.08M, EPS −$2.10
- Quarter ended Jun 30, 2023: revenue $19.8M (up 418.0% year over year), net income −$11.9M, EPS −$3.13
- Quarter ended Mar 31, 2023: revenue $8.78M (up 164.7% year over year), net income −$25.1M, EPS −$6.75
- Quarter ended Dec 31, 2022 (from the annual report): revenue $10.6M (up 67.2% year over year), net income −$28.5M, EPS −$36.96
- Quarter ended Sep 30, 2022: revenue $7.36M (down 69.4% year over year), net income −$23.9M, EPS −$0.22
- Quarter ended Jun 30, 2022: revenue $3.82M (down 94.4% year over year), net income −$31.0M, EPS −$0.46
- Quarter ended Mar 31, 2022: revenue $3.32M (down 79.7% year over year), net income −$28.2M, EPS −$0.46
- Quarter ended Dec 31, 2021 (from the annual report): revenue $6.34M, net income −$22.3M, EPS −$0.36
- Quarter ended Sep 30, 2021: revenue $24.0M, net income −$11.3M, EPS −$0.19
DTIL cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$65.8M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$58.4M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$84.1M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$45.8M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$10.9M, share buybacks n/a
DTIL balance sheet
- Jun 30, 2026: cash $86.1M, total assets $126M, total liabilities $80.6M, shareholders' equity $45.3M
- Mar 31, 2026: cash $99.4M, total assets $144M, total liabilities $67.8M, shareholders' equity $76.1M
- Dec 31, 2025: cash $111M, total assets $154M, total liabilities $62.2M, shareholders' equity $92.2M
- Sep 30, 2025: cash $44.9M, total assets $93.5M, total liabilities $76.9M, shareholders' equity $16.6M
- Jun 30, 2025: cash $62.2M, total assets $109M, total liabilities $74.9M, shareholders' equity $34.1M
- Mar 31, 2025: cash $77.2M, total assets $124M, total liabilities $75.1M, shareholders' equity $49.3M
- Dec 31, 2024: cash $85.9M, total assets $136M, total liabilities $80.0M, shareholders' equity $56.4M
- Sep 30, 2024: cash $98.8M, total assets $153M, total liabilities $88.4M, shareholders' equity $64.9M
What is DTIL's revenue?
PRECISION BIOSCIENCES INC reported $45.1M of revenue over its last four quarters, through June 30, 2026.
Is DTIL profitable?
No. PRECISION BIOSCIENCES INC lost $52.7M over the last four quarters.
What is DTIL's EPS?
Diluted earnings per share over the last four quarters were −$1.23; −$1.26 in the latest quarter.